|From: singhtelecom (Rep: 959)||Date: 07/01/2018 04:39|
|Forum: AVEO Pharmaceuticals, Inc. - Msg #743||Thread #674018722 (Rec: 0) |
|in North America as a treatment for renal cell carcinoma and other cancers. In October 2017, AVEO announced the completion of a pre-planned interim futility analysis of the Phase 3 TIVO-3 trial, the Company's randomized, controlled, multi-center, open-label study to compare tivozanib to sorafenib (NEXAVAR) in subjects with aRCC. Based on the results of the futility analysis, which were reviewed by an independent statistician, the study continued as planned without modification. The analysis did not allow for early stopping due to efficacy to assure adequate follow-up for the key secondary endpoint of overall survival. In May, the company detailed that the pre-specified number of progression free survival (PFS) events required to trigger data analysis of the Phase 3 TIVO-3 trial have not been reached at this time and, as such, the Company is amending its guidance for the anticipated topline data readout from the seco|
TheLion.com | About Us | Agreement & Disclaimer | Privacy | Twitter
© 1999- TheLion.com, Inc.